{"title": "Potent neutralization of 2019 novel coronavirus by recombinant ACE2-Ig", "doi": "10.1101/2020.02.01.929976", "citation_id": "2020.02.01.929976v2", "date": "2020-02-03", "laguage": "en", "journal_title": "bioRxiv", "first_page": "2020.02.01.929976", "abstract": "<h3>Abstract</h3>\n<p>2019-nCoV, which is a novel coronavirus emerged in Wuhan, China, at the end of 2019, has caused at least infected 11,844 as of Feb 1, 2020. However, there is no specific antiviral treatment or vaccine currently. Very recently report had suggested that novel CoV would use the same cell entry receptor, ACE2, as the SARS-CoV. In this report, we generated a novel recombinant protein by connecting the extracellular domain of human ACE2 to the Fc region of the human immunoglobulin IgG1. An ACE2 mutant with low catalytic activity was also used in the study. The fusion proteins were then characterized. Both fusion proteins has high affinity binding to the receptor-binding domain (RBD) of SARS-CoV and 2019-nCoV and exerted desired pharmacological properties. Moreover, fusion proteins potently neutralized SARS-CoV and 2019-nCoV <i>in vitro.</i> As these fusion proteins exhibit cross-reactivity against coronaviruses, they could have potential applications for diagnosis, prophylaxis, and treatment of 2019-nCoV.</p>", "twitter_description": "2019-nCoV, which is a novel coronavirus emerged in Wuhan, China, at the end of 2019, has caused at least infected 11,844 as of Feb 1, 2020. However, there is no specific antiviral treatment or vaccine currently. Very recently report had suggested that novel CoV would use the same cell entry receptor, ACE2, as the SARS-CoV. In this report, we generated a novel recombinant protein by connecting the extracellular domain of human ACE2 to the Fc region of the human immunoglobulin IgG1. An ACE2 mutant with low catalytic activity was also used in the study. The fusion proteins were then characterized. Both fusion proteins has high affinity binding to the receptor-binding domain (RBD) of SARS-CoV and 2019-nCoV and exerted desired pharmacological properties. Moreover, fusion proteins potently neutralized SARS-CoV and 2019-nCoV in vitro. As these fusion proteins exhibit cross-reactivity against coronaviruses, they could have potential applications for diagnosis, prophylaxis, and treatment of 2019-nCoV.", "full_text_html_url": "https://www.biorxiv.org/content/10.1101/2020.02.01.929976v2.full", "public_url": "https://www.biorxiv.org/content/10.1101/2020.02.01.929976v2", "abstract_html_url": "https://www.biorxiv.org/content/10.1101/2020.02.01.929976v2.abstract", "pdf_url": "https://www.biorxiv.org/content/biorxiv/early/2020/02/03/2020.02.01.929976.full.pdf", "rights": "\u00a9 2020, Posted by Cold Spring Harbor Laboratory. The copyright holder for this pre-print is the author. All rights reserved. The material may not be redistributed, re-used or adapted without the author's permission.", "publisher": "Cold Spring Harbor Laboratory", "pisa": "biorxiv;2020.02.01.929976v2", "access_rights": "restricted", "authors": ["Changhai Lei", "Wenyan Fu", "Kewen Qian", "Tian Li", "Sheng Zhang", "Min Ding", "Shi Hu"]}